in vitro News and Research

RSS

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

In a statement today, StemSave(TM), Inc., the market leader in the field of stem cell recovery and cryo-preservation lauds research published in the November issue of the European Cells and Materials Journal citing the reconstruction of the human mandible bone with autologous dental pulp stem cells.

9 Dec 2009

Catholics for Choice's statement on restriction of abortion coverage

"Today, Senator Ben Nelson (D-Nebraska) put the policy priorities of the U.S. Catholic bishops before the needs of women nationwide. Originally, Senator Nelson maintained that the abortion language in the healthcare bill was not a make-or-break factor in his vote.

8 Dec 2009

Gene positions may offer a new method of cancer diagnosis

Certain genes switch their nuclear position in tumor cells, offering a potential new method of diagnosing cancer, say researchers from the National Cancer Institute. The study by Meaburn et al. will be published online December 7, 2009 (www.jcb.org) and in the December 14, 2009 print issue of the Journal of Cell Biology (JCB).

8 Dec 2009

Non-clinical data of CK-2017357 presented by Cytokinetics

Cytokinetics, Incorporated announced today that both a poster and an oral presentation summarizing non-clinical data regarding CK-2017357, a novel fast skeletal troponin activator, were presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 in Barcelona, Spain.

8 Dec 2009

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.

8 Dec 2009

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

KFDA approves RPC's Onko-Sure in Vitro Diagnostic cancer test

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) announced today the Korean Food & Drug Administration (KFDA) has approved RPC's Onko-Sure™ in Vitro Diagnostic cancer test for routine clinical testing and government reimbursement throughout Korea.

4 Dec 2009

Bishop-endorsed healthcare system can undermine medical treatments and preventative measures

If the Catholic bishops have their way, many medical treatments and preventative measures we take for granted may be under threat. The pressure that the US bishops have brought to bear on the debate over healthcare reform has been widely reported.

3 Dec 2009

AclarusDx Alzheimer’s test now available as RUO product

ExonHit Therapeutics is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.

3 Dec 2009

Over twenty new drug metabolism assays launched by Absorption Systems

Absorption Systems, a leader in drug safety and ADMET (absorption, distribution, metabolism, excretion and toxicity) testing, today announced the introduction of a more complete series of drug metabolism assays designed to support the pharmaceutical R&D process, from early-stage discovery through late-stage clinical development.

2 Dec 2009

AFA to host a webinar on Catholics and IVF

On Monday, The American Fertility Association will host a webinar entitled Catholics and IVF: A Pastoral Approach, presented by Father Jon Pedigo. IVF, or In Vitro Fertilization, is a form of assisted reproductive technology (ART) often used by couples and individuals who are having difficulty conceiving a child naturally. During the IVF process, one or more embryos are implanted into a woman's uterus and the remaining, unused embryos are destroyed, frozen, or donated.

2 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. S-kaly from the Universit- de Montr-al.

26 Nov 2009

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

A fortuitous discovery that grew out of a collaboration between UCLA engineers and physicians could potentially offer hope to the nearly 10 million Americans who suffer from peripheral arterial disease.

26 Nov 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Merck Chimie advances to the next phase in commercializing Beads, reports CardioGenics Holdings

CardioGenics Holdings Inc., a developer of technology and products targeting the immunoassay segment of the IVD testing market, reports that Merck Chimie S.A.S. ("Merck Chimie") is progressing to the next phase of the commercialization of CardioGenics' proprietary silver coated paramagnetic Beads ("Beads").

25 Nov 2009

in vitro News and Research

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

Catholics for Choice's statement on restriction of abortion coverage

Gene positions may offer a new method of cancer diagnosis

Non-clinical data of CK-2017357 presented by Cytokinetics

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

KFDA approves RPC's Onko-Sure in Vitro Diagnostic cancer test

Bishop-endorsed healthcare system can undermine medical treatments and preventative measures

AclarusDx Alzheimer’s test now available as RUO product

Over twenty new drug metabolism assays launched by Absorption Systems

AFA to host a webinar on Catholics and IVF

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

DiaMedica to acquire all issued and outstanding shares of Sanomune

MUHC's innovative treatment for HIV patients passes first clinical trial successfully

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Merck Chimie advances to the next phase in commercializing Beads, reports CardioGenics Holdings

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News